About Oragenics
Oragenics is a company based in Tampa (United States) founded in 1996. The company has 3 employees as of December 31, 2024. Oragenics offers products and services including Vaccine Program, Pipeline, and Science and Technology. Oragenics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Tampa, United States
- Employees 3 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oragenics Inc.
-
Annual Revenue
Not available
-
Net Profit
-$10.57 M (USD)48.84as on Dec 31, 2024
-
EBITDA
-$10.56 M (USD)0.78as on Dec 31, 2024
-
Latest Funding Round
$850 K (USD), Post-IPO
Aug 04, 2023
-
Investors
HHS
& 3 more
-
Employee Count
3
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Oragenics
Oragenics is a publicly listed company on the AMEX with ticker symbol OGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Oragenics
Oragenics offers a comprehensive portfolio of products and services, including Vaccine Program, Pipeline, and Science and Technology.
Develops vaccines targeting brain-related conditions and unmet needs.
Manages research pipelines for pharmaceutical innovations.
Provides tools for brain-related drug advancement and publications.
People of Oragenics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Oragenics
Investors in Oragenics
Oragenics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Precigen and National Institute of General Medical Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Basic research is supported to advance medical sciences.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases
|
Locked | Locked | Locked |
Investor details for Oragenics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oragenics
Investment portfolio details for Oragenics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oragenics
Detailed financials for Oragenics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oragenics Comparisons
Peer comparison for Oragenics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oragenics
Oragenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Oragenics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oragenics
Complete news archive for Oragenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oragenics
Oragenics was founded in 1996 and raised its 1st funding round 12 years after it was founded.
Oragenics is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Alan Joslyn is the current CEO of Oragenics.
As of Dec 31, 2024, the latest employee count at Oragenics is 3.
Oragenics was founded in 1996 and is based in Tampa, United States. Operations focus on the biotechnology sector, where treatments for infectious diseases and oral mucositis are developed, complemented by probiotics aimed at oral health maintenance. The lead candidate, AG013, is formulated as a live biotherapeutic oral rinse that delivers Trefoil Factor 1 to mucosal tissues in the oral cavity. Leadership is provided by CEO and President Alan Joslyn.
Oragenics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Oragenics offers Vaccine Program, Pipeline, and Science and Technology.
Yes, Oragenics is publicly traded on AMEX under the ticker symbol OGEN.
Oragenics has 4 investors. Key investors include HHS, Precigen, National Institute of General Medical Sciences, and National Science Foundation.
The ticker symbol of Oragenics is OGEN on AMEX.